VNDA

$3.88+3.47%visit website

Vanda Pharmaceuticals Inc.

Market Cap

$235M

Live price × SEC shares (Oct 22, 2026)

Sector

Health Care

Industry

Biotechnology

Beta (raw)

0.71

60mo monthly vs SPY

P/E (TTM)

N/M

TTM to Sep 2026 · negative earnings

P/S (TTM)

1.0

TTM to Sep 2026 · revenue

P/B

1.2

Mkt cap / shareholders' equity

EV/EBITDA (TTM)

—

EV / TTM EBITDA

Loading…

Financial Statements

USD thousands	Q4 FY2025 Dec 31, 2025	Q1 FY2026 Mar 31, 2026	Q2 FY2026 Jun 30, 2026	Q3 FY2026 Sep 30, 2026	TTM Sep 30, 2026
Revenue	57,216	51,718	50,529	69,815	229,278
Research & development	29,006	28,435	36,953	27,622	122,016
Selling, general & administrative	62,978	68,361	71,838	59,575	262,752
Operating income	(40,353)	(50,224)	(63,809)	(23,521)	(177,907)
Pretax income	(38,002)	(48,424)	(62,384)	(22,388)	(171,198)
Income tax	103,185	143	129	174	103,631
Net income	(141,187)	(48,567)	(62,513)	(22,562)	(274,829)
EPS (basic) ($)		(0.82)	(1.04)	(0.37)	(4.62)
EPS (diluted) ($)		(0.82)	(1.04)	(0.37)	(4.62)
Weighted avg. shares (basic)		59,460	60,227	60,465
Weighted avg. shares (diluted)		59,460	60,227	60,465

Source: SEC XBRL filings (10-K, 10-Q). Per-share data in dollars; shares in thousands. Latest: 10-Q filed Oct 29, 2026, period ended Sep 30, 2026. flagged for review— withheld, failed a consistency check restated or split-adjustedhover a value for its source

Showing the last 5 quarters. 62 more quarters, back to Jun 2010, with Tormere Pro.

Corporate Events (8-K)

14 filings in 12 months · 0 with priority itemsFull history →

Filed	Items	Filing
Oct 28, 2026 accepted 4:07 PM ET	2.02Earnings release	Document SEC ↗
Aug 5, 2026 accepted 4:04 PM ET	2.02Earnings release	Document SEC ↗
Jun 5, 2026 accepted 4:38 PM ET	5.07Shareholder vote	Document SEC ↗
May 6, 2026 accepted 4:06 PM ET	2.02Earnings release	Document SEC ↗
Apr 22, 2026 accepted 5:23 PM ET	5.02Officer / director change	Document SEC ↗
Apr 2, 2026 accepted 4:30 PM ET	5.02Officer / director change	Document SEC ↗
Mar 10, 2026 accepted 4:47 PM ET	7.01Reg FD disclosure	Document SEC ↗
Feb 23, 2026 accepted 7:00 AM ET	8.01Other events	Document SEC ↗
Feb 19, 2026 accepted 4:31 PM ET	5.02Officer / director change	Document SEC ↗
Feb 11, 2026 accepted 4:05 PM ET	2.02Earnings release	Document SEC ↗

Signals

purchases / sales, 90d

Short Volume

63%

W/W +22.1pp

Market & Alt Data

News

Factor Profile

Pro

Pro feature

Fama-French factor analysis is available on the Pro plan.

Upgrade to Pro

Sort by

Type

Trade Date	Filed	Owner	Role	Type	Shares	Price	Value	Owned After
2026-03-02	2026-03-04	Williams Timothy	SVP & General Counsel	Sale	42.4K	$8.27	$351K	377.4K	View
2026-03-02	2026-03-04	Moran Kevin Patrick	SVP, CFO & Treasurer	Sale	42.4K	$8.27	$351K	411.4K	View
2026-03-02	2026-03-04	Wijkstrom Joakim	SVP, Chief Marketing Officer	Sale	30.8K	$8.27	$255K	333.5K	View
2026-03-02	2026-03-04	Polymeropoulos Mihael Hristos	Director & President and CEO	Sale	156.2K	$8.17	$1.28M	2.70M	View
2026-03-02	2026-03-04	Birznieks Gunther	SVP, Business Development	Sale	42.4K	$8.27	$351K	494.2K	View

1–5 of 6

1 / 2

Recent News

Vanda Pharmaceuticals Inc. (VNDA) Stock Price, News, Quote & History

Yahoo! Finance Canada · 2026-11-04

Vanda Pharmaceuticals Announces Participation at November 2026 Investor Conferences

Yahoo · 2026-11-03

Two Vanda conference chats may be watched live in November

Stock Titan · 2026-11-03

Vanda Pharmaceuticals Inc. (VNDA) stock price, news, quote and history

Yahoo Finance UK · 2026-11-02

Vanda Pharmaceuticals Inc (VNDA) (Q3 2026) Earnings Call Highlights: Revenue Jumps 24% as ...

Yahoo · 2026-11-01

Vanda Pharmaceuticals (VNDA) Stock Forecast & Analyst Ratings

Moomoo · 2026-11-01

Vanda Pharmaceuticals Inc. Q3 2026 Earnings Call Summary

Yahoo · 2026-10-29

12 Health Care Stocks Moving In Thursday's Pre-Market Session

Benzinga · 2026-10-29

Steve Jobs' Son Says GLP-1 Weight Loss Drugs Could Be Among Most Important Medicines Ever, With Potential Impact on Cancer

Benzinga · 2026-10-29

Vanda (VNDA) Q3 2026 Earnings Call Transcript

Yahoo · 2026-10-29

Vanda Pharmaceuticals Inc. (VNDA) Q3 2026 Earnings Call Transcript

SeekingAlpha · 2026-10-29

Vanda Pharmaceuticals Q3 Earnings Call Highlights

Yahoo · 2026-10-29

Vanda Pharmaceuticals (VNDA) Reports Q3 Loss, Tops Revenue Estimates

Yahoo · 2026-10-28

Vanda: Q3 Earnings Snapshot

Yahoo · 2026-10-28

Vanda Pharmaceuticals Reports Third Quarter 2026 Financial Results

Yahoo · 2026-10-28

Informational purposes only, not investment advice.

Date	Insider	Type	Shares	Value
2026-03-02	Williams Timothy	S	42,434	$350,755.2
2026-03-02	Moran Kevin Patrick	S	42,442	$350,821.33
2026-03-02	Wijkstrom Joakim	S	30,800	$254,589.72
2026-03-02	Polymeropoulos Mihael Hristos	S	156,235	$1M
2026-03-02	Birznieks Gunther	S	42,431	$350,730.4

VNDA

Financial Statements

Corporate Events (8-K)

Signals

Factor Profile

Recent News

Vanda Pharmaceuticals Inc. (VNDA)

Reporting Insiders

Factor Profile

Corporate Events (8-K)